Sputnik V is the third vaccine authorized to be used in India, followed by local Covishield and Covaxin vaccines.
The Russian vaccine was developed by the Gamaleya National Research Institute of Epidemiology and Microbiology last year and its clinical trials in India are being conducted by the Doctor Reddy Laboratory.
The multinational pharmaceutical company, based in Hyderabad, also signed an agreement with the Russian Direct Investment Fund for the supply of Sputnik V vaccine doses in India.
Previously, a committee of experts recommended on Monday the authorization of emergency use of Sputnik V vaccines, which showed positive results in its clinical trials, 91.6% of efficacy.
India has administered over 108.5 million Covid-19 vaccine doses to date, according to data released by the Ministry of Health and Family Welfare.